Condition
Cree Leukoencephalopathy
Total Trials
3
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Early P 1 (1)
Trial Status
Active Not Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07300397Not ApplicableActive Not RecruitingPrimary
Single Patient Investigational Treatment for Cree Leukoencephalopathy
NCT06594016Unknown
Expanded Access to Fosigotifator
NCT07272525Early Phase 1Active Not RecruitingPrimary
Research Study for Single-Patient Treatment of Cree Leukoencephalopathy/Vanishing White Matter Disease
Showing all 3 trials